Publicaciones en colaboración con investigadores/as de University of Calgary (45)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  3. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1376-1382

  4. Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

    Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114

  5. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  6. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

  7. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222

2022

  1. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)

    Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 2, pp. 659-670

  2. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

    Blood, Vol. 140, Núm. 8, pp. 839-850

  3. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

2021

  1. A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus

    Gastroenterology

  2. Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus

    Gastroenterology, Vol. 161, Núm. 3, pp. 748-755

  3. Factors associated with fears due to COVID-19: A scleroderma patient-centered intervention network (SPIN) COVID-19 cohort study

    Journal of Psychosomatic Research, Vol. 140

  4. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

    Human Genetics and Genomics Advances, Vol. 2, Núm. 3

  5. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

    Respiratory Medicine, Vol. 178

  6. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

    Respiratory Medicine, Vol. 177

  7. The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial

    Trials, Vol. 22, Núm. 1

  8. Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: A report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group

    BMJ Open, Vol. 11, Núm. 11

2020

  1. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

    British Journal of Cancer, Vol. 123, Núm. 5, pp. 793-802

  2. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study

    Journal of Clinical Oncology